Amicus Therapeutics

Here are 5 Biopharmaceutical Companies on the Rise
Wall St Cheat Street
Sat, 10/13/12 - 11:55 am
Pluristem
Ariad Pharmaceuticals
Sarepta Therapeutics
Amicus Therapeutics
StemCells
5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments
Seeking Alpha
Tue, 10/9/12 - 04:21 pm
PLX
Pluristem Therapeutics
Ariad Pharmaceuticals
Ponatinib
Sarepta
eteplirsen
Fabry's disease
Amicus Therapeutics
StemCells
Healthcare Review: PharmAthene & Codexis Slump On News, Amicus Rises
Yahoo/Reuters
Sat, 08/11/12 - 11:23 am
PharmAthene
Codexis
Arena Pharmaceuticals
Pfizer
Amicus Therapeutics
Celldex
Amicus Therapeutics' CEO Hosts GSK Expanded Fabry Collaboration Call (Transcript)
Seeking Alpha
Sun, 07/22/12 - 08:32 am
GSK
Amicus Therapeutics
Amicus Therapeutics and GlaxoSmithKline Expand Fabry Disease Collaboration
Yahoo
Tue, 07/17/12 - 04:17 pm
GSK
Amicus Therapeutics
Fabry's disease
A Promising $5 Biotech Stock With Major Insider Buying
Seeking Alpha
Sun, 07/1/12 - 12:07 pm
Amicus Therapeutics
22 Biopharma Stocks With Breakout Potential in 2012
Seeking Alpha
Tue, 05/22/12 - 11:25 am
Ziopharm
Zalicus
EXACT Sciences
Geron
Lexicon Pharmaceuticals
Nektar
Vical
Celgene
Celsion
ChemoCentryx
Clovis Oncology
Eli Lilly
JNJ
Pfizer
Elan
Biomarin
Biogen Idec
Auxilium
Arqule
Anthera
Acadia
Amicus Therapeutics
Vertex Pharmaceuticals
How Much Further Can Rare Diseases Carry BioMarin?
Seeking Alpha
Thu, 03/29/12 - 05:19 pm
Biomarin
Amicus Therapeutics
Sanofi
Vertex
Rare diseases: All the rage in Big Pharma
Fierce Pharma
Thu, 11/18/10 - 08:17 am
Big Pharma
GSK
Shire
Genzyme
Amicus Therapeutics
Hyperion Therapeutics
CMC Biologics
Edimer
Biotech Ends October With Almost $1B in IPOs, $3B in M&A Activity, $3B in Possible Partnerships
Seeking Alpha
Sun, 10/31/10 - 11:35 am
Teva Pharmaceuticals
Sanofi
Pfizer
Pacific Biosciences
Merck
Macrogenics
Hikma
GSK
BMP Sunstone
biotech
Baxter International
Amicus Therapeutics
Immune Design
MedImmune
Amicus Therapeutics Agreement with GSK - Call Transcript
Seeking
Sun, 10/31/10 - 10:56 am
GSK
Amicus Therapeutics
GlaxoSmithKline licenses Amicus drug in $230M deal
Bizjournals.com
Fri, 10/29/10 - 11:38 am
Amicus Therapeutics
GSK
licensing
Amigal
Fabry's disease
Small-Cap Biotech Spikes 50% On P&G Deal
Yahoo/IndieResearch
Wed, 08/25/10 - 12:26 pm
P&G
Somaxon
Amarin
Repros Therapeutics
Chelsea Therapeutics
Amicus Therapeutics
GSK: Rare Diseases Now Big Business
WSJ Online
Mon, 02/8/10 - 12:35 pm
GSK
Prosensa
Neurosearch
JCS Pharmaceuticals
Amicus Therapeutics
Aldagen
Genzyme: Shire Chomping at the Bit
Seeking Alpha
Tue, 01/19/10 - 09:37 am
Shire
Genzyme
Amicus Therapeutics
Seattle Genetics, Amicus plunge; AVI, DepoMed rally
Marketwatch
Mon, 10/5/09 - 03:04 pm
Seattle Genetics
Amicus Therapeutics
AVI BioPharma
biotech
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Yahoo/PR NewsWire
Sat, 10/3/09 - 09:36 am
Pilcera
Gaucher disease
Amicus Therapeutics
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Yahoo
Sat, 03/28/09 - 11:39 am
Amicus Therapeutics
Genzyme Playing Defense
Motley Fool
Mon, 02/23/09 - 04:52 pm
Genzyme
AstraZeneca
Amicus Therapeutics
Biotech Clinical Trials to Watch in 2009
TheStreet.com
Thu, 12/18/08 - 03:43 pm
drug trials
Alnylam
Amgen
Amicus Therapeutics
Arena Pharmaceuticals
Biogen Idec
Chelsea Therapeutics
Genentech
Gilead Sciences
Human Genome Sciences
InterMune
Isis Pharmaceuticals
Neurocrine
ONYX Pharmaceuticals
Orexigen
Osiris Therapeutics
Poniard
Rigel
United Therapeutics
Synta

Pages